BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35945417)

  • 1. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer.
    Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
    Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
    Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
    Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflicting roles of
    Oshi M; Gandhi S; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(10):5094-5110. PubMed ID: 34765314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
    Oshi M; Kawaguchi T; Yan L; Peng X; Qi Q; Tian W; Schulze A; McDonald KA; Narayanan S; Young J; Liu S; Morris LG; Chan TA; Kalinski P; Matsuyama R; Otsuji E; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3628-3644. PubMed ID: 34354864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
    Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy.
    Oshi M; Gandhi S; Huyser MR; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(9):4421-4437. PubMed ID: 34659896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
    Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
    Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.
    Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
    Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
    Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
    Murthy V; Oshi M; Tokumaru Y; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3674-3687. PubMed ID: 34354867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of KAM score to predict metastasis and worse survival in breast cancer.
    McDonald KA; Oshi M; Kawaguchi T; Qi Q; Peng X; Yamada A; Opyrchal M; Liu S; Yao S; Otsuji E; Yan L; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(11):5388-5401. PubMed ID: 34873467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased intratumor heterogeneity, angiogenesis and epithelial to mesenchymal transition pathways in metaplastic breast cancer.
    Chouliaras K; Oshi M; Asaoka M; Tokumaru Y; Khoury T; Endo I; Ishikawa T; Takabe K
    Am J Cancer Res; 2021; 11(9):4408-4420. PubMed ID: 34659895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.